SS-31 10mg vs 50mg
A research-first comparison of the 10mg SS-31 vial and the 50mg SS-31 vial, focused on total-mass workflow, reconstitution planning, and storage discipline for lyophilized elamipretide research formats.
Update History ▾
Initial publication
The 10mg and 50mg SS-31 vials compare as workflow formats, not as different peptides. Published literature describes SS-31 (elamipretide) as the same cardiolipin-binding tetrapeptide regardless of vial size.[1][2] The 10mg format is usually easier for small or intermittent laboratory work, while the 50mg format makes sense when a lab already has a fixed aliquot plan, a defined stock concentration, and strict post-reconstitution handling control.[3][4]
- Mechanism stays the same: the format question is operational, not mechanistic.
- 10mg is the cleaner low-throughput choice: it usually means less diluent, less leftover stock, and fewer repeated handling events.
- 50mg demands a stronger SOP: the larger vial only helps if the lab already knows its aliquot sizes and storage workflow.
- More mass does not mean more stability: post-reconstitution handling still needs conservative control.
- Choose by assay scale: smaller or changing protocols usually favor 10mg; repeat bench workflows can justify 50mg.
Same SS-31, Different Format Burden
The primary literature describes SS-31, also known as elamipretide or MTP-131, as the tetrapeptide D-Arg-Dmt-Lys-Phe-NH2 that associates with cardiolipin-containing mitochondrial membranes.[1][2] That identity does not change between a 10mg vial and a 50mg vial. What changes is how much total lyophilized material the lab has to convert into stock solution and protect once the vial is opened.
This is why the 10mg vs 50mg question is best answered through workflow. The smaller vial generally gives tighter control when the lab is iterating or using the material slowly. The larger vial can improve efficiency when the protocol is already fixed, but it also creates more exposure if concentration planning and aliquoting are left to guesswork.
What Changes Between 10mg and 50mg in Practice?
| Workflow factor | 10mg vial | 50mg vial |
|---|---|---|
| Total mass per stopper | Lower | Higher |
| Diluent needed to hold the same stock concentration | Lower | 5x the 10mg vial |
| Best fit for exploratory work | Stronger | Only if the lab truly needs that much material in one cycle |
| Best fit for repeat assays | Works, but more reorders may be needed | Stronger when aliquots and labels are already standardized |
| Risk of leftover reconstituted stock | Usually lower | Usually higher unless aliquoted quickly |
None of those differences imply anything about human dosing. They only describe the amount of stock solution a lab must manage after the lyophilized cake has been reconstituted.
Reconstitution Math: Keep the Stock Strength Fixed
The easiest way to see the operational difference is to fix the target concentration and compare diluent volume. If the protocol wants a 5mg/mL stock, the 50mg vial requires five times the water of the 10mg vial. The same ratio holds at 10mg/mL or 20mg/mL.
10mg vial
- 5mg/mL stock: add 2mL diluent
- 10mg/mL stock: add 1mL diluent
- 20mg/mL stock: add 0.5mL diluent
50mg vial
- 5mg/mL stock: add 10mL diluent
- 10mg/mL stock: add 5mL diluent
- 20mg/mL stock: add 2.5mL diluent
Those examples are format math, not dose instructions. Use the bacteriostatic water guide to decide the diluent and sterile workflow, then document the chosen stock concentration in the bench record before the first withdrawal.
Compare the current SS-31 research pages, then keep the chosen format aligned with your storage SOP and reconstitution notes.
Open Catalog →Why the 50mg Format Requires Stronger Aliquot Control
A 50mg vial can be efficient when the same SS-31 workflow repeats often enough to justify a larger stock batch. The cost of that efficiency is that the lab must protect a larger reconstituted volume from contamination, temperature drift, and repeated stopper access.
Why 10mg is easier to manage
- Smaller stock volume is easier to finish or replace
- Less chance of carrying leftover solution into the next run
- Lower penalty if the protocol changes midstream
- Simpler for single-operator or pilot workflows
Why 50mg can make sense
- More efficient for repeat assays with the same stock target
- Better suited to preplanned aliquot containers
- Reduces vial turnover in scheduled workflows
- Can help when multiple assay days are already locked in
That tradeoff is why the larger vial should be paired with an aliquot-first mindset rather than treated like a casual bigger bottle. If the lab does not have those controls, the larger format can create more avoidable handling risk than it removes.
Storage Guardrails After Reconstitution
The official Bacteriostatic Water for Injection label describes a multiple-dose diluent with 0.9% benzyl alcohol and explicitly calls for aseptic technique during entry and withdrawal.[3] The CDC guidance adds the operational rule that an opened multi-dose vial should be dated and discarded within 28 days unless the manufacturer states otherwise.[4]
Those rules help with the diluent side of the workflow. They do not automatically prove a specific in-use window for reconstituted SS-31 itself. Without compound-specific stability instructions, a lab should take the conservative route: minimize unnecessary time in solution, aliquot promptly when needed, and cross-check the broader workflow against the peptide stability and storage guide.
Which SS-31 Format Fits Your Bench Workflow?
| Workflow pattern | Preferred format | Why |
|---|---|---|
| Pilot or method-development work | 10mg | Less stock volume to manage while conditions are still changing. |
| Intermittent assay access | 10mg | Lower leftover risk and fewer forced storage decisions. |
| Repeat assays with a fixed SOP | 50mg | More efficient when concentration and aliquot planning are already settled. |
| Shared multi-operator workflow | 50mg only if controlled | Works best when vial access, labels, and aliquot ownership are documented clearly. |
When in doubt, the safer default is usually the 10mg SS-31 vial. Move to the 50mg format when the protocol scale truly requires it and the storage process can defend it.
Our Research Standards
This page uses primary SS-31 literature for molecule-identity claims and official injection-safety sources for the handling rules. Where the evidence supports a mechanistic statement, we say so directly. Where the page extends those rules into lab-format workflow, we keep the inference narrow and operational. Read our editorial policy →
- Szeto HH. Cell-permeable, mitochondrial-targeted, peptide antioxidants. AAPS J. 2006;8(2):E277-E283. Primary overview of the SS peptide class and SS-31 structure. PubMed.
- Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Chem Soc. 2013;135(37):13832-13834. DOI.
- Pfizer. Bacteriostatic Water for Injection, USP. Official label describing 0.9% benzyl alcohol, repeated withdrawals, aseptic technique, and prompt use of reconstituted drug solutions unless otherwise directed. Official label PDF.
- Centers for Disease Control and Prevention. Preventing Unsafe Injection Practices. Guidance on aseptic technique and dating opened multi-dose vials within 28 days unless the manufacturer states otherwise. CDC guidance.
Open the SS-31 Formats
Compare the 10mg and 50mg research pages, then pair the chosen format with the storage and reconstitution references before the first withdrawal.
View Catalog →